Bioventus' CEO Ken Reali left his post on April 4.

Aurora-based University of Colorado Medicine opened the CU Medicine Regenerative Medicine, Hand and Spine Center in Englewood.

Here are five updates in orthobiologics and regenerative medicine to know from the first quarter of 2023:

The world's first viable bone matrix that provides lineage-committed bone cells, LifeNet Health's ViviGen MIS, is now available for use in trauma procedures. 

Here are five updates in regenerative medicine since the end of December:

Orthobiologics company Royal Biologics has commercially launched a new platelet-rich plasma system, Bioincyte. 

A three-year study of Creative Medical Technology Holdings' StemSpine procedure found it was effective for addressing chronic lower back pain.

Orthobiologics company DiscGenics shared data supporting its IDCT (rebonuputemcel) allogeneic discogenic progenitor cell therapy for lumbar degenerative disc disease.

Apex Biologix has chosen Jim Rogers to be the company's next CEO. 

ChitogenX, formerly OrthoRTI, shared its third quarter results for fiscal year 2023.

Here are five top-read Becker's headlines on orthobiologics and regenerative medicine in 2022:

A study published in Neurology International found fusion rates of 98.6 percent with Orthofix's Trinity Elite cellular bone allograft, the devicemaker said Dec. 22.

NorthBay Health Orthopedics in Vacaville, Calif. added platelet-rich plasma injections for knee injuries, according to a Dec. 18 announcement in the Daily Republic.

Here are five updates in the orthobiologics industry since Oct. 17:

Shriners Children's Hawaii in Honolulu is the first hospital in the state to use the Bridge-Enhanced ACL Restoration, or BEAR, implant, ABC affiliate KITV reported Nov. 23.

Swedish-based bone graft substitute manufacturer Bonesupport, which received FDA approval for its bone infection indicator Cerament G in May, has found that the new product saves an average of $28,000 per patient according to a Nov. 21 email sent to Becker's. 

A Hartford, Conn.-based insurer has dropped its lawsuit that aimed to avoid defending Aziyo Biologics in litigation over tainted spine allografts.

Bone Biologics and the University of California Los Angeles plan to begin their joint venture clinical trial testing the efficacy of their bone graft substitute treatment for spinal fusion, trauma, osteoporosis and other bone-related indications in 2023.

Janet Conway, MD, completed the first U.S. cases using Bonesupport's Cerament G for osteomyelitis.

Orthobiologics company Ossio closed a $38.5 million series C financing round.